IDOR-1117-2520 is now in a Phase 2 proof-of-concept trial in psoriasis, with the potential to expand into additional autoimmune conditions where the CCR6-CCL20 pathway plays a pathogenic role.

To help Class 9 students score high marks in the Annual Exam 2026, we have compiled complete CBSE Class 9 Study Material 2025-26 including syllabus, deleted topics, NCERT books, NCERT solutions, MCQs, ...

Abstract: Colorectal cancer (CRC) is a significant public health concern worldwide. Its early detection is critical since it dictates treatment options and significantly impacts survival time. A ...

Could Alex Bregman be a fit in Toronto? Ishika Samant / Getty Images ORLANDO, Fla. — The Toronto Blue Jays were the talk of baseball at the GM meetings in Las Vegas in early November. The feel-good ...

“TY1 is the first exomer – a new class of drugs that address tissue damage in unexpected ways.” TY1 has the structure of existing RNA drugs, and works like its natural version – amplifying the ...

LONDON - Tissue Regenix Group plc (AIM:TRX) has conditionally secured £17.5 million through Secured Convertible Loan Notes to be issued to major shareholder Harwood Private Equity VI L.P. and ...

Zurich, Switzerland, December 03, 2025 – MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269) ...

We're excited to announce our .NET 9 SDK release! Note: these are the base SDKs that add support for the platforms in question, if you are looking for .NET MAUI ...

1 Department of Health Science, UniCamillus-Saint Camillus International Medical University, Rome, Italy 2 Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, Rome, Italy ...